Red Beet (Beta vulgaris) Extract and Betanin Attenuate Valproic Acid–Induced Autism-Like Neurobehavioral and Molecular Alterations via Modulation of Oxidative Stress, Neuroinflammation, Apoptosis, and Reelin Signaling

Résumé

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition linked to social-communication and behavioral impairments, with emerging evidence implicating oxidative stress, neuroinflammation, and disrupted neurotransmission in its pathogenesis. Natural compounds with antioxidant and anti-inflammatory potential are explored as alternative therapeutic agents. This study investigated the neuroprotective effects of Beta vulgaris leaf ethanolic extract and its bioactive compound, betanin, in a rat model of ASD induced by prenatal valproic acid (VPA) exposure. Male neonatal rats, born to dams prenatally exposed to VPA (400 mg/kg b.wt on E12.5), were postnatally (PND 23 to PND 37) treated with either water (VPA/W), extract solvent (VPA/SE), B. vulgaris extract (200 mg/kg b.wt, VPA/EE), or betanin (25 mg/kg b.wt, VPA/BT), and compared to rats from control dams that received the same postnatal treatments (CW, CSE, CEE, and CBT, respectively). Behavioral assessments showed that VPA/EE and VPA/BT significantly improved sociability and social novelty deficits. Biochemical analyses revealed that both treatments enhanced GABA levels, reduced oxidative stress markers (MDA), elevated antioxidant defenses (GSH and CAT), and decreased pro-inflammatory TNF-α. Apoptotic markers (BCL2 and Caspase-3) were normalized, and histopathological brain abnormalities were ameliorated. Also, Reelin gene expression, suppressed by VPA, was significantly upregulated following treatment. While VPA/BT showed greater efficacy in improving sociability and neurotransmitter balance, VPA/EE exhibited broader molecular modulation. These findings concluded that B. vulgaris extract and betanin possess substantial neuroprotective properties via antioxidant, anti-inflammatory, anti-apoptotic, and neuromodulatory pathways. Their potential as adjunctive treatments for ASD warrants further clinical investigation. Graphical abstract

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0